Insight Molecular Diagnostics Inc. is a precision diagnostics company specializing in the development and commercialization of advanced molecular diagnostic tests for both clinical and research applications. With a core focus on transplant medicine and oncology, the company’s product portfolio includes laboratory-developed tests, kitted research-use-only assays, and kitted clinical tests targeting key unmet needs in patient care. Notable offerings are its VitaGraft Kidney and VitaGraft Liver tests, which use blood-based detection of donor-derived cell-free DNA to monitor for organ transplant rejection, and the GraftAssure suite, which leverages droplet digital PCR technology for highly sensitive transplant monitoring. In the oncology space, Insight Molecular Diagnostics is developing DetermaCNI—a blood-based assay to detect early progression after one cycle of cancer treatment—and DetermaIO, a test predicting response to immunotherapies by assessing the tumor microenvironment. The company also engages in biomarker discovery, assay development, and supports clinical trials for pharmaceutical partners. Through collaboration with industry leaders such as Bio-Rad Laboratories, Insight Molecular Diagnostics contributes to both research and in-vitro diagnostic advancements. Founded in 2009 and now headquartered in Nashville, Insight Molecular Diagnostics plays a significant role in improving patient outcomes across the healthcare landscape by enabling personalized and real-time intervention through precision diagnostics.